Advertisement
Clinical Therapeutics
Advanced searchSave search
Research Article| Volume 31, ISSUE 3, P632-643, March 2009

Download started.

Ok

Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure

DOI:https://doi.org/10.1016/j.clinthera.2009.03.019
Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure
Previous ArticleA comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes
Next ArticleResults of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background: The addition of hydralazine/isosorbide dinitrate (H-ISDN) to a standard heart failure treatment regimen in the African-American Heart Failure Trial was associated with a 43% reduction in mortality. However, the effectiveness of H-ISDN in a community sample of African-American patients and other racial/ethnic groups is unknown.
      Objective: The aim of this study was to assess the associations between treatment with H-ISDN and mortality or hospitalization for heart failure in veterans with the disease.
      Methods: For this retrospective cohort study, electronic data on outpatient prescriptions, comorbidity, and other heart failure risk factors were analyzed in veterans with heart failure. Patients were classified based on whether they were prescribed H-ISDN and subclassified based on race/ethnicity (African American, Hispanic, or white). Patients who were prescribed H-ISDN were subclassified based on time of initiation of H-ISDN treatment (0–121, 122–365, or >365 days after diagnosis). Data were analyzed using propensity-adjusted Cox regression analyses, with exposure to H-ISDN modeled as a time-varying covariate.
      Results: Data from 76,828 veterans were analyzed (98% men, 2% women). H-ISDN prescription was not associated with the risk of death in 5 of the 9 subgroups predefined by race/ethnicity or time of initiation of H-ISDN; however, H-ISDN was associated with an increased risk of death in the 4 subgroups with longer times to initiation. H-ISDN was associated with a significantly increased risk of heart failure hospitalization in all but 1 of the 9 subgroups. The risk of both mortality and hospitalization associated with H-ISDN was significantly lower in African-American patients than in those who were Hispanic or white. Concurrent prescription of other, evidence-based heart failure therapies (eg, angiotensin-converting enzyme inhibitors, β-blockers, and combinations) had strong, statistically significant associations with reduced mortality.
      Conclusions: In this population of veterans with heart failure, H-ISDN prescription was not associated with significant reductions in mortality or hospitalization in any of the subgroups defined by race/ethnicity and time of initiation of H-ISDN analyzed compared with the group that did not receive H-ISDN. It is possible, or even likely, that unmeasured differences in important risk factors—particularly heart failure severity and left ventricular dysfunction—between the group that received H-ISDN and the one that did not masked a beneficial effect of H-ISDN. Therefore, our conclusions must be regarded as hypothesis generating and need to be tested in subsequent randomized trial(s).

      Key words:

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Cohn JN
        • Archibald DG
        • Ziesche S
        • et al.
        Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
        N Engl J Med. 1986; 314: 1547-1552
        • Cohn JN
        • Johnson G
        • Ziesche S
        • et al.
        A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
        N Engl J Med. 1991; 325: 303-310
      3. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [published correction appears in N Engl J Med. 1992;327:1768].
        N Engl J Med. 1992; 327: 685-691
        • Pfeffer MA
        • Braunwald E
        • Moyé LA
        • et al.
        • for the SAVE Investigators
        Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial.
        N Engl J Med. 1992; 327: 669-677
        • Køber L
        • Torp-Pedersen C
        • Carlsen JE
        • et al.
        • for the Trandolapril Cardiac Evaluation (TRACE) Study Group
        A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.
        N Engl J Med. 1995; 333: 1670-1676
        • Konstam MA
        • Dracup K
        • Baker DW
        • et al.
        Heart failure: Evaluation and care of patients with left ventricular systolic dysfunction.
        J Card Fail. 1995; 1: 183-187
        • Hunt SA
        • Baker DW
        • Chin MH
        • et al.
        • for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; and the Heart Failure Society of America
        ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America.
        Circulation. 2001; 104: 2996-3007
        • Hunt SA
        • Abraham WT
        • Chin MH
        • et al.
        • for the American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; and Heart Rhythm Society
        ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation; Endorsed by the Heart Rhythm Society.
        Circulation. 2005; 112: e154-e235
        • Taylor AL
        • Ziesche S
        • Yancy C
        • et al.
        • for the African-American Heart Failure Trial Investigators
        Combination of isosorbide dinitrate and hydralazine in blacks with heart failure [published correction appears in N Engl J Med. 2005;352:1276].
        N Engl J Med. 2004; 351: 2049-2057
        • World Health Organization
        International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland, WHO1977
        • Bonow RO
        • Bennett S
        • Casey DE
        • et al.
        • for the American College of Cardiology; American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures); Heart Failure Society of America
        ACC/AHA clinical performance measures for adults with chronic heart failure. A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America.
        J Am Coll Cardiol. 2005; 46: 1144-1178
        • Veterans Affairs Information Resource Center
        VIReC research user guide: VHA pharmacy prescription data, 2003.
        http://www.virec.research.va.gov/References/RUG/RUG-Pharmacy03rev.pdf
        (Accessed September 18, 2005)
        • Sohn MW
        • Arnold N
        • Maynard C
        • Hynes DM
        Accuracy and completeness of mortality data in the Department of Veterans Affairs.
        Popul Health Metr. 2006; 4: 2
        • Quan H
        • Sundararajan V
        • Halfon P
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139
        • Cox DR
        Regression models and life tables.
        J R Stat Soc. 1972; B34: 187-220
        • Fisher LD
        • Lin DY
        Time-dependent covariates in the Cox proportional-hazards regression model.
        Annu Rev Public Health. 1999; 20: 145-157
        • Allison PD
        Survival Analysis Using SAS: A Practical Guide. Cary, NC, SAS Publishing1995
        • Zhou Z
        • Rahme E
        • Abrahamowicz M
        • Pilote L
        Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: A comparison of methods.
        Am J Epidemiol. 2005; 162: 1016-1023
        • Elixhauser A
        • Steiner C
        • Harris DR
        • Coffey RM
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • Solomon SD
        • Anavekar N
        • Skali H
        • et al.
        • for the Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators
        Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.
        Circulation. 2005; 112: 3738-3744
        • Curtis JP
        • Sokol SI
        • Wang Y
        • et al.
        The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure.
        J Am Coll Cardiol. 2003; 42: 736-742
        • Bhatia RS
        • Tu JV
        • Lee DS
        • et al.
        Outcome of heart failure with preserved ejection fraction in a population-based study.
        N Engl J Med. 2006; 355: 260-269
        • Owan TE
        • Hodge DO
        • Herges RM
        • et al.
        Trends in prevalence and outcome of heart failure with preserved ejection fraction.
        N Engl J Med. 2006; 355: 251-259
        • Schneeweiss S
        • Avorn J
        A review of uses of health care utilization databases for epidemiologic research on therapeutics.
        J Clin Epidemiol. 2005; 58: 323-337
        • McMahon AD
        • Evans JM
        • McGilchrist MM
        • et al.
        Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology.
        Pharmacoepidemiol Drug Saf. 1998; 7: 275-280
        • Suissa S
        Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: Immortal time bias in observational studies.
        Am J Respir Crit Care Med. 2003; 168: 49-53
        • Shah BR
        • Laupacis A
        • Hux JE
        • Austin PC
        Propensity score methods gave similar results to traditional regression modeling in observational studies: A systematic review.
        J Clin Epidemiol. 2005; 58: 550-559
        • Austin PC
        • Grootendorst P
        • Anderson GM
        A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study.
        Stat Med. 2007; 26: 734-753
        • Austin PC
        • Mamdani MM
        A comparison of propensity score methods: A case-study estimating the effectiveness of post-AMI statin use.
        Stat Med. 2006; 25: 2084-2106
        • Glynn RJ
        • Schneeweiss S
        • Stürmer T
        Indications for propensity scores and review of their use in pharmacoepidemiology.
        Basic Clin Pharmacol Toxicol. 2006; 98: 253-259
        • Tam SW
        • Sabolinski ML
        • Worcel M
        • et al.
        Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: The V-HeFT paradox.
        Clin Pharmacokinet. 2007; 46: 885-895
        • Lindenauer PK
        • Pekow P
        • Wang K
        • et al.
        Perioperative beta-blocker therapy and mortality after major noncardiac surgery.
        N Engl J Med. 2005; 353: 349-361
        • Lindenauer PK
        • Pekow P
        • Wang K
        • et al.
        Lipid-lowering therapy and inhospital mortality following major noncardiac surgery.
        JAMA. 2004; 291: 2092-2099

      Article info

      Publication history

      Accepted: January 26, 2009

      Identification

      DOI: https://doi.org/10.1016/j.clinthera.2009.03.019

      Copyright

      © 2009 Excerpta Medica Inc. All rights reserved. Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX